FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $78,571 | -22.2% | 37,062 | +74.7% | 0.00% | – |
| Q2 2023 | $100,979 | -96.9% | 21,214 | -93.5% | 0.00% | -100.0% |
| Q4 2022 | $3,308,309 | -37.7% | 327,880 | +38.4% | 0.00% | -40.0% |
| Q3 2022 | $5,309,000 | -8.9% | 236,890 | +0.7% | 0.01% | 0.0% |
| Q2 2022 | $5,829,000 | -30.6% | 235,235 | +8.6% | 0.01% | -16.7% |
| Q1 2022 | $8,400,000 | -20.1% | 216,675 | +20.7% | 0.01% | -14.3% |
| Q4 2021 | $10,507,000 | +29.0% | 179,585 | +30.7% | 0.01% | +16.7% |
| Q3 2021 | $8,147,000 | -27.9% | 137,444 | +5.6% | 0.01% | -25.0% |
| Q2 2021 | $11,296,000 | +5.5% | 130,154 | +0.3% | 0.01% | 0.0% |
| Q1 2021 | $10,704,000 | +847.3% | 129,822 | +944.7% | 0.01% | +700.0% |
| Q4 2020 | $1,130,000 | – | 12,427 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |